Osborne Clarke advises MVM Partners in the EUR 32 million Series A financing of Avanzanite Bioscience

Osborne Clarke has advised MVM Partners, a leading life-science PE firm, on its EUR 32 million Series A investment in Avanzanite Bioscience, a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases.

This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio and to advance toward its 2032 vision of a pan-European platform with more than 10 rare disease alliances - setting a new European standard for orphan medicine commercialisation and patient access.

The Osborne Clarke core deal team consisted of Amsterdam Partner Herke van Hulst and Associate Angela Saldanha and was supported by Amsterdam Partner Jim Margry.  

Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, big pharma and medical device companies in the market.